Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 37

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
 income5,008 4,749 11,903 8,652 Interest expense(4,695)(3,884)(9,275)(7,200)Gain on early extinguishment of debt— 7,518 — 7,518 Other, net(10,739)(39)(6,338)(198)          Total other (expense) income, net(10,426)8,344 (3,710)8,772 (Loss) income before income taxes(1,927)36,584 6,779 50,224 Income tax expense(2,920)(17,698)(6,814)(22,359)Net (loss) income$(4,847)$18,886 $(35)$27,865 Net (loss) income per common share:    Basic net (loss) income per common share$(0.11)$0.41 $(0.00)$0.60 Diluted net (loss) income per common share$(0.11)$0.39 $(0.00)$0.58 Weighted average common shares outstanding:       Basic45,459 46,174 45,867 46,337      Diluted45,459 50,539 45,867 51,366     

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 5

Table of Contents

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In thousands)

(Unaudited)

Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Net (loss) income$(4,847)$18,886 $(35)$27,865 Other comprehensive income (loss):  Net unrealized loss on investments, net of tax(45)(52)(131)(160)Foreign currency translation adjustments2,756 5 3,850 18 Total other comprehensive income (loss)2,711 (47)3,719 (142)Comprehensive (loss) income$(2,136)$18,839 $3,684 $27,723 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |